BG108585A - Използване на atazanavir при лечение на hiv - Google Patents

Използване на atazanavir при лечение на hiv Download PDF

Info

Publication number: BG108585A
Authority: BG; Bulgaria
Prior art keywords: hiv; atazanavir; ldl; cholesterol; hiv protease
Prior art date: 2001-08-31

Application number

BG108585A

Other languages

Bulgarian (bg)

English (en)

Inventor

Clifford Bechtold

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-31

Filing date

2004-02-17

Publication date

2005-04-30

2004-02-17 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2005-04-30 Publication of BG108585A publication Critical patent/BG108585A/bg

Links

AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 title claims abstract description 61
AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 title claims abstract description 59
108010019625 Atazanavir Sulfate Proteins 0.000 title claims abstract description 59
229960003277 atazanavir Drugs 0.000 title claims abstract description 59
238000002560 therapeutic procedure Methods 0.000 title claims abstract description 13
239000004030 hiv protease inhibitor Substances 0.000 claims abstract description 37
238000008214 LDL Cholesterol Methods 0.000 claims abstract description 29
108010028554 LDL Cholesterol Proteins 0.000 claims abstract description 22
229940122440 HIV protease inhibitor Drugs 0.000 claims abstract description 20
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 15
238000000034 method Methods 0.000 claims abstract description 14
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims abstract description 8
108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 7
208000031886 HIV Infections Diseases 0.000 claims abstract description 5
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 5
101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 claims abstract description 5
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 5
230000001747 exhibiting effect Effects 0.000 claims abstract description 4
150000003626 triacylglycerols Chemical class 0.000 claims description 18
229960001852 saquinavir Drugs 0.000 claims description 17
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 17
230000002401 inhibitory effect Effects 0.000 claims description 15
230000036470 plasma concentration Effects 0.000 claims description 14
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 9
229960000884 nelfinavir Drugs 0.000 claims description 9
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 7
229960001936 indinavir Drugs 0.000 claims description 5
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 5
229960001830 amprenavir Drugs 0.000 claims description 4
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 4
108010010369 HIV Protease Proteins 0.000 claims description 2
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 2
229960004525 lopinavir Drugs 0.000 claims description 2
238000006467 substitution reaction Methods 0.000 claims 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 13
229960000311 ritonavir Drugs 0.000 description 13
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 10
239000003112 inhibitor Substances 0.000 description 10
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 9
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 9
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 7
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 7
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 6
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 6
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
229960002656 didanosine Drugs 0.000 description 6
229960001203 stavudine Drugs 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
229940079593 drug Drugs 0.000 description 5
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 5
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 5
230000000840 anti-viral effect Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
230000002503 metabolic effect Effects 0.000 description 4
230000001629 suppression Effects 0.000 description 4
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
208000031226 Hyperlipidaemia Diseases 0.000 description 3
102100034343 Integrase Human genes 0.000 description 3
102000007330 LDL Lipoproteins Human genes 0.000 description 3
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
238000011225 antiretroviral therapy Methods 0.000 description 3
229960001627 lamivudine Drugs 0.000 description 3
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
239000002777 nucleoside Substances 0.000 description 3
150000003833 nucleoside derivatives Chemical class 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000009097 single-agent therapy Methods 0.000 description 3
229960002555 zidovudine Drugs 0.000 description 3
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
230000000798 anti-retroviral effect Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000007211 cardiovascular event Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002028 premature Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000003826 tablet Substances 0.000 description 2
LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
229960003804 efavirenz Drugs 0.000 description 1
-1 efavirenz Chemical compound 0.000 description 1
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229960000838 tipranavir Drugs 0.000 description 1
SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BG108585A 2001-08-31 2004-02-17 Използване на atazanavir при лечение на hiv BG108585A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31674501P	2001-08-31	2001-08-31

Publications (1)

Publication Number	Publication Date
BG108585A true BG108585A (bg)	2005-04-30

Family

ID=23230468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108585A BG108585A (bg)	2001-08-31	2004-02-17	Използване на atazanavir при лечение на hiv

Country Status (27)

Country	Link
US (1)	US20030045501A1 (et)
EP (1)	EP1420799B1 (et)
JP (1)	JP2005501880A (et)
KR (1)	KR20040029447A (et)
CN (1)	CN1245988C (et)
AT (1)	ATE341332T1 (et)
AU (1)	AU2002332610B2 (et)
BG (1)	BG108585A (et)
BR (1)	BR0211544A (et)
CA (1)	CA2458807A1 (et)
CZ (1)	CZ2004288A3 (et)
DE (1)	DE60215189T2 (et)
DK (1)	DK1420799T3 (et)
EE (1)	EE200400065A (et)
ES (1)	ES2274119T3 (et)
HR (1)	HRP20040181A2 (et)
HU (1)	HUP0401091A2 (et)
IL (1)	IL159849A0 (et)
IS (1)	IS7158A (et)
MX (1)	MXPA04001721A (et)
NO (1)	NO20040803L (et)
NZ (1)	NZ530722A (et)
PL (1)	PL367873A1 (et)
RU (1)	RU2316341C2 (et)
WO (1)	WO2003020206A2 (et)
YU (1)	YU12204A (et)
ZA (1)	ZA200401412B (et)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE428411T1 (de) *	2003-11-07	2009-05-15	Jj Pharma Inc	Hdl-verstärkende kombinationstherapie-komplexe
US20050148523A1 (en) *	2003-12-15	2005-07-07	Colonno Richard J.	Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
AR066972A1 (es)	2007-06-12	2009-09-23	Concert Pharmaceuticals Inc	Derivados azapeptidicos
EP2178512B1 (en) *	2007-06-22	2011-03-09	Bristol-Myers Squibb Company	Tableted compositions containing atazanavir
SI2178513T1 (sl) *	2007-06-22	2011-05-31	Bristol Myers Squibb Co	Tabletni sestavki vsebujoäśi atazanavir
DK2170292T3 (da) *	2007-06-22	2014-04-07	Bristol Myers Squibb Holdings Ireland	Atazanavirholdige sammensætninger i tabletform
ES2360336T3 (es) *	2007-06-22	2011-06-03	Bristol-Myers Squibb Company	Composiciones en comprimidos que contienen atazanavir.
AU2008320642A1 (en) *	2007-10-29	2009-05-07	Cipla Limited	Novel antiretroviral combination
CN101249138B (zh) *	2008-03-28	2012-03-21	中国人民解放军军事医学科学院野战输血研究所	一种含五味子乙醇提取物的抗艾滋病药物组合物
EP2552429A1 (en) *	2010-04-02	2013-02-06	Phivco-1 LLC	Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2188638C2 (ru) *	1996-04-04	2002-09-10	Шионоги Энд Ко., Лтд.	Анти-вич-композиция, содержащая имидазольные производные

2002
- 2002-08-21 HR HR20040181A patent/HRP20040181A2/xx not_active Application Discontinuation
- 2002-08-21 KR KR10-2004-7002851A patent/KR20040029447A/ko not_active Ceased
- 2002-08-21 AU AU2002332610A patent/AU2002332610B2/en not_active Ceased
- 2002-08-21 NZ NZ530722A patent/NZ530722A/en unknown
- 2002-08-21 IL IL15984902A patent/IL159849A0/xx unknown
- 2002-08-21 JP JP2003524520A patent/JP2005501880A/ja not_active Withdrawn
- 2002-08-21 EP EP02797744A patent/EP1420799B1/en not_active Expired - Lifetime
- 2002-08-21 CN CNB028166868A patent/CN1245988C/zh not_active Expired - Fee Related
- 2002-08-21 CA CA002458807A patent/CA2458807A1/en not_active Abandoned
- 2002-08-21 YU YU12204A patent/YU12204A/sh unknown
- 2002-08-21 US US10/225,754 patent/US20030045501A1/en not_active Abandoned
- 2002-08-21 MX MXPA04001721A patent/MXPA04001721A/es active IP Right Grant
- 2002-08-21 ES ES02797744T patent/ES2274119T3/es not_active Expired - Lifetime
- 2002-08-21 AT AT02797744T patent/ATE341332T1/de not_active IP Right Cessation
- 2002-08-21 CZ CZ2004288A patent/CZ2004288A3/cs unknown
- 2002-08-21 EE EEP200400065A patent/EE200400065A/et unknown
- 2002-08-21 BR BR0211544-1A patent/BR0211544A/pt not_active IP Right Cessation
- 2002-08-21 DK DK02797744T patent/DK1420799T3/da active
- 2002-08-21 WO PCT/US2002/026675 patent/WO2003020206A2/en not_active Ceased
- 2002-08-21 RU RU2004106787/14A patent/RU2316341C2/ru not_active IP Right Cessation
- 2002-08-21 DE DE60215189T patent/DE60215189T2/de not_active Expired - Fee Related
- 2002-08-21 HU HU0401091A patent/HUP0401091A2/hu unknown
- 2002-08-21 PL PL02367873A patent/PL367873A1/xx not_active Application Discontinuation
2004
- 2004-02-17 BG BG108585A patent/BG108585A/bg unknown
- 2004-02-19 IS IS7158A patent/IS7158A/is unknown
- 2004-02-20 ZA ZA200401412A patent/ZA200401412B/en unknown
- 2004-02-24 NO NO20040803A patent/NO20040803L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ2004288A3 (cs)	2004-12-15
MXPA04001721A (es)	2004-05-31
NZ530722A (en)	2007-11-30
DE60215189T2 (de)	2007-10-25
CN1547476A (zh)	2004-11-17
ES2274119T3 (es)	2007-05-16
ATE341332T1 (de)	2006-10-15
AU2002332610B2 (en)	2007-11-08
WO2003020206A3 (en)	2003-10-02
HK1061640A1 (en)	2004-09-30
RU2316341C2 (ru)	2008-02-10
JP2005501880A (ja)	2005-01-20
HRP20040181A2 (en)	2004-08-31
HUP0401091A2 (hu)	2004-08-30
US20030045501A1 (en)	2003-03-06
WO2003020206A2 (en)	2003-03-13
ZA200401412B (en)	2005-03-18
YU12204A (sh)	2006-08-17
CN1245988C (zh)	2006-03-22
EE200400065A (et)	2004-06-15
EP1420799A2 (en)	2004-05-26
IL159849A0 (en)	2004-06-20
KR20040029447A (ko)	2004-04-06
BR0211544A (pt)	2004-07-13
IS7158A (is)	2004-02-19
CA2458807A1 (en)	2003-03-13
DE60215189D1 (de)	2006-11-16
DK1420799T3 (da)	2007-01-15
NO20040803L (no)	2004-02-24
PL367873A1 (en)	2005-03-07
EP1420799A4 (en)	2004-11-24
EP1420799B1 (en)	2006-10-04

Publication	Publication Date	Title
Savarino et al.	2001	The anti-HIV-1 activity of chloroquine
Klimke et al.	2020	Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection
Hughes et al.	2011	Protease inhibitors for patients with HIV-1 infection: a comparative overview
HUE026849T2 (en)	2016-08-29	Therapeutic combination containing dolutegravir, abacavir and lamivudine
WO2016036759A1 (en)	2016-03-10	Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
Wynn et al.	2004	Antiretrovirals, part 1: overview, history, and focus on protease inhibitors
JP2019504857A (ja)	2019-02-21	Ｈｉｖおよびエイズの治療および予防方法
D'Abbraccio et al.	2015	Efficacy and tolerability of integrase inhibitors in antiretroviral-naive patients.
AU2002332610B2 (en)	2007-11-08	Use of atazanavir in HIV therapy
AU2004273773B2 (en)	2008-01-24	Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
McKinnon et al.	2009	Simplification strategies to reduce antiretroviral drug exposure: progress and prospects
JP2023123440A (ja)	2023-09-05	合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
KR20080081358A (ko)	2008-09-09	Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
AU2002332610A1 (en)	2003-06-05	Use of atazanavir in HIV therapy
Jain et al.	2021	Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19: A review
WO2004054586A1 (en)	2004-07-01	Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US9463194B2 (en)	2016-10-11	Methods of treating patients co-infected with HIV and tuberculosis
Fuster et al.	2005	Review of atazanavir: a novel HIV protease inhibitor
RU2203047C2 (ru)	2003-04-27	Композиция для снижения содержания церамидов
Liao et al.	2023	Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS
HK1061640B (en)	2007-05-25	Use of atazanavir in hiv therapy
HK1079981B (zh)	2007-10-12	含有阿巴卡韦和阿洛夫定的药物制剂及其用途
Kahn	1996	The clinical use of didanosine
Vizcarra et al.	2019	Short communication Efficacy and safety of dolutegravir plus boosted‑darunavir dual therapy among highly treatment‑experienced patients
Sension	2004	Initial Therapy for Human Immunodeficiency Virus: Broadening the Options